Medtronic Announces Preliminary Results of MiniMed Group, Inc. Exchange Offer

Medtronic's oversubscribed MiniMed share exchange will fully divest its MiniMed stake.

What the company is saying

Medtronic plc (NYSE:MDT) is reporting the preliminary results of its exchange offer, which allows shareholders to swap Medtronic ordinary shares for shares of MiniMed Group, Inc. (NASDAQ:MMED). The company emphasizes that the offer was oversubscribed, with 298,024,452 Medtronic shares tendered against only 55,032,401 to be accepted, reflecting strong shareholder participation. Medtronic is clear that all of its remaining 252,813,348 MiniMed shares will be exchanged, using a fixed ratio of 4.5939 MiniMed shares per Medtronic share accepted. The announcement details the treatment of odd-lot shareholders and proration for the rest, highlighting that only about 18.3% of tendered shares will be accepted, pending final guaranteed delivery validation. The company states that after completion, it will no longer own any MiniMed shares. The communication is process-oriented, factual, and avoids promotional language, focusing on mechanics and next steps.

What the data suggests

The data shows that 298,024,452 Medtronic shares were validly tendered, including 93,311,404 by guaranteed delivery and 757,890 by odd-lot holders. Only 55,032,401 shares will be accepted for exchange, resulting in a preliminary proration factor of approximately 18.3%. All of Medtronic's remaining 252,813,348 MiniMed shares will be distributed, at an exchange ratio of 4.5939 MiniMed shares per Medtronic share accepted. Odd-lot shareholders who tendered all their shares are exempt from proration. The oversubscription indicates strong demand for MiniMed shares or for participating in the transaction. The final proration factor will be confirmed on October 14, 2026. The release is comprehensive about the transaction mechanics but does not disclose financial impacts, pro forma ownership, or strategic rationale beyond the divestment itself.

Analysis

The announcement is a factual, process-driven update on the preliminary results of Medtronic's exchange offer for MiniMed shares. The language is precise and avoids promotional or exaggerated claims, focusing on share counts, exchange ratios, and the mechanics of proration. The only forward-looking statements pertain to the finalization of the proration factor and the administrative return of unaccepted shares, both of which are routine and imminent (within days). There are no claims about future financial performance, synergies, or strategic benefits, nor is there any attempt to frame the transaction in an overly positive light. No large capital outlay or long-dated benefit is described; the transaction is mechanical and near completion. The data fully supports the narrative, and there is no evidence of narrative inflation.

Risk flags

• ●There is execution risk in the final delivery of shares tendered by guaranteed delivery procedures; if some are not delivered, the proration factor could change, affecting shareholder outcomes.
• ●The announcement does not provide financial or strategic context for the divestment, leaving investors without information on the impact to Medtronic's balance sheet, earnings, or future business model.
• ●Shareholders who tendered but are not accepted due to proration may face short-term uncertainty until the final factor is confirmed and shares are returned, potentially affecting liquidity or trading decisions.

Bottom line

Medtronic is completing a full divestment of its MiniMed stake through a heavily oversubscribed share exchange, with only 18.3% of tendered Medtronic shares to be accepted and all 252,813,348 MiniMed shares distributed. The process is nearly complete, with final administrative steps and proration confirmation due by October 14, 2026. The announcement is transparent on mechanics but omits any discussion of financial or strategic impacts, so investors cannot yet assess the effect on Medtronic's earnings, cash, or future direction. The most actionable takeaway is that Medtronic will no longer own MiniMed, and the exchange's immediate settlement will finalize shareholder positions. Investors should watch for the final proration factor and any subsequent disclosures on the financial consequences of this transaction.

Announcement summary

(NYSE:MDT) Medtronic plc announced the preliminary results of its previously announced exchange offer to exchange shares of common stock of MiniMed Group, Inc. (NASDAQ:MMED) for outstanding Medtronic ordinary shares. The exchange offer expired at 12:00 midnight, New York City time, at the end of the day on October 9, 2026. Medtronic has decided to exchange all of its remaining interest in MiniMed, totaling 252,813,348 shares of MiniMed common stock. Under the terms of the exchange offer, 4.5939 shares of MiniMed common stock will be exchanged for each Medtronic ordinary share accepted in the exchange offer. According to the exchange agent, Equiniti Trust Company, LLC, 298,024,452 Medtronic ordinary shares were validly tendered and not validly withdrawn, including 93,311,404 shares tendered by notice of guaranteed delivery and 757,890 shares tendered in aggregate by 'odd-lot' shareholders (holders of fewer than 100 shares) not subject to proration. Medtronic intends to accept 55,032,401 of the tendered shares in exchange for 252,813,348 shares of MiniMed common stock. Because the exchange offer was oversubscribed, Medtronic is accepting only a portion of its ordinary shares that were validly tendered and not validly withdrawn, on a pro rata basis in proportion to the number of shares tendered. Shareholders who owned odd-lots and have validly tendered all of their shares will not be subject to proration, in accordance with the terms of the exchange offer. Based on the total number of Medtronic ordinary shares reported to be tendered prior to the expiration of the exchange offer, it is estimated that approximately 18.3% of the tendered Medtronic ordinary shares will be exchanged, assuming all shares tendered by guaranteed delivery procedures are delivered under the terms of the exchange offer. This preliminary proration factor is subject to change based on the number of tendered shares that satisfy the guaranteed delivery procedures. Medtronic expects to announce the final proration factor on October 14, 2026, promptly following the expiration of the guaranteed delivery period. Medtronic ordinary shares tendered but not accepted for exchange will be returned to the tendering shareholders in book-entry form promptly after the final proration factor is announced. Following the completion of the exchange offer, Medtronic will not retain any of the outstanding shares of MiniMed common stock. Goldman Sachs & Co. LLC and BofA Securities, Inc. are the dealer managers for the exchange offer. Equiniti Trust Company, LLC is the exchange agent. D.F. King & Co., Inc. is the information agent for the exchange offer. MiniMed has filed with the SEC a registration statement on Form S-4 that includes a Prospectus. Medtronic has filed with the SEC a Schedule TO, which contains important information about the exchange offer.

Disagree with this article?